Study of the pharmaceutical component of the clinical protocol for the treatment of patients with Hodgkin's lymphoma in Ukraine.

Abstract

n the treatment of patients with Hodgkin's lymphoma (HL), chemotherapy (ChT) occupies one of the priority places. Therefore, the issue of effective pharmaceutical support for patients with HL is relevant and socially important. The aim of the study. To analyze the data of the "Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care "Non-Hodgkin's lymphomas and Hodgkin's lymphoma" (order of the Ministry of Health of Ukraine № 866 of 08.10.2013 "On the approval and implementation of medical and technological documents on the standardization of medical care in non-Hodgkin's lymphomas and Hodgkin's lymphoma") to comply with the requirements of legislative and regulatory acts that regulate the circulation of medicinal products.